Histone Deacetylase Inhibitor Romidepsin Inhibits De Novo HIV-1 Infections

Adjunct therapy with the histone deacetylase inhibitor (HDACi) romidepsin increases plasma viremia in HIV patients on combination antiretroviral therapy (cART). However, a potential concern is that reversing HIV latency with an HDACi may reactivate the virus in anatomical compartments with suboptima...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Jønsson, Kasper L., Tolstrup, Martin, Vad-Nielsen, Johan, Kjær, Kathrine, Laustsen, Anders, Andersen, Morten N., Rasmussen, Thomas A., Søgaard, Ole S., Østergaard, Lars, Denton, Paul W., Jakobsen, Martin R.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2015
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468708/
https://ncbi.nlm.nih.gov/pubmed/25896701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00574-15
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items